Information: Detta är inte den senaste versionen av datamodellen. Du hittar en versionsöversikt till vänster under versioner. Den senaste versionen hittar du här.
Information:
Fel:
ID
14867
Beskrivning
A Phase III Trial For Patients With Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00191152
Länk
https://clinicaltrials.gov/show/NCT00191152
Nyckelord
Versioner (2)
- 2016-05-02 2016-05-02 -
- 2016-06-26 2016-06-26 -
Uppladdad den
2 maj 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Breast Cancer NCT00191152
Eligibility Breast Cancer NCT00191152
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT00191152
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
ID.1
Item
histologic or cytologic confirmation of breast cancer with locally advanced and/or metastatic disease
boolean
C0019638 (UMLS CUI [1,1])
C0678222 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,3])
C0678222 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,3])
ID.2
Item
patients may have received prior neo-adjuvant or adjuvant taxane regimen as long as it has been greater than or equal to 6 months since completion of the regimen
boolean
C3541958 (UMLS CUI [1])
ID.3
Item
patients may have had 0-1, but no more than one prior course of chemotherapy for metastatic disease
boolean
C1514457 (UMLS CUI [1])
ID.4
Item
patients must have either measurable or non-measurable (evaluable) disease
boolean
C1513040 (UMLS CUI [1])
ID.5
Item
prior radiation therapy allowed of less than 25% of the bone marrow
boolean
C1522449 (UMLS CUI [1,1])
C0332152 (UMLS CUI [1,2])
C0332152 (UMLS CUI [1,2])
ID.6
Item
second primary malignancy (except in situ carcinoma of the cervix or adequately treated nonmelanomatous carcinoma of the skin or other malignancy treated at least 5 years previously with no evidence of recurrence)
boolean
C0751623 (UMLS CUI [1])
ID.7
Item
parenchymal or leptomeningeal brain metastases
boolean
C0220650 (UMLS CUI [1])
ID.8
Item
peripheral neuropathy greater than or equal to grade 2
boolean
C0031117 (UMLS CUI [1])
ID.9
Item
prior treatment with gemcitabine and capecitabine will not be allowed. prior treatment with a taxane in the metastatic setting will not be allowed. prior taxane therapy in the neo-adjuvant or adjuvant setting is allowed if completion of therapy greater than or equal to 6 months prior to enrollment.
boolean
ID.10
Item
active cardiac disease not controlled by therapy and/or myocardial infarction within the preceding 6 months.
boolean
C0018799 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0205318 (UMLS CUI [1,2])
ID.11
Item
concomitant herceptin is not allowed
boolean
C1707479 (UMLS CUI [1,1])
C0338204 (UMLS CUI [1,2])
C0338204 (UMLS CUI [1,2])